GSK Highlights R&D Productivity Gains In First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.